Greece

Blossom currently tracks 5 psychedelic clinical trials connected to Greece, including 2 active studies. The country page also links to 3 stakeholders, giving the page ecosystem context beyond registered studies.

Ask Blossom about this country

Data updated July 15, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inGreece.

1
Blossom tracks 5 psychedelic clinical trials connected to Greece, including 2 active studies.
2
Visible trial compounds include Esketamine, Ketamine and Psilocybin.
3
Visible trial topics include Major Depressive Disorder (MDD), Chronic Pain and Treatment-Resistant Depression (TRD).
4
The country page links to 3 stakeholders in Blossom's ecosystem data.
5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.

Research and Access Snapshot

Blossom currently tracks 5 psychedelic clinical trials connected to Greece, including 2 active studies.

Active trials: 2
Total trials: 5
Stakeholders: 5
Events: 0

Top Compounds

Esketamine(3)
Ketamine(2)
Psilocybin(1)

Active Trial Preview

View all trials →

Medical Access

Greece maintains a restrictive controlled-substances regime under Law 4139/2013; licensed pharmaceutical psychedelics that have EU marketing authorisations (currently esketamine/Spravato) are available under tight clinical controls, but routine public reimbursement and broad medical access for classic psychedelics (psilocybin, MDMA, DMT, etc.) do not exist outside approved clinical research. Off-label clinical use of ketamine for anesthesia and some private off-label psychiatric uses occurs, but most other compounds remain scheduled with no authorized...

View trials→View stakeholders→Open access guide→

Research Landscape

What the 5 registered trials connected to Greece look like when you line them up. Counts come from Blossom’s trial records as of July 2026.

What's live right now, and what stopped?

Sourced

Registry status of all 5 Greece trials Blossom tracks. Orange marks trials recruiting or opening.

Recruiting or opening: 360%
Completed: 240%

Browse trials →

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Regulatory Status

The linked medical access and reimbursement guide summarises Greece as "Medical Only (Private)". Greece maintains a restrictive controlled-substances regime under Law 4139/2013; licensed pharmaceutical psychedelics that have EU marketing authorisations (currently esketamine/Spravato) are available under tight clinical controls, but routine public reimbursement and broad medical access for classic psychedelics (psilocybin, MDMA, DMT, etc.) do not exist outside approved clinical research. Off-label clinical use of ketamine for anesthesia and some private off-label psychiatric uses occurs, but most other compounds remain scheduled with no authorized medical use outside clinical trials or special authorised programmes.